Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b multiple ascending dose study of OM336 in active autoimmune diseases
jRCT2011260057Phase 1Recruiting
- Sponsor
- Lakefront Biotherapeutics
- Start
- Oct 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of gamgertamig in Sjögren's syndrome, Autoimmune Myopathies and pemphigus, sponsored by Lakefront Biotherapeutics. Primary endpoint: Safety and tolerability. Started Oct 2026; status: recruiting.
02
Drugs
gamgertamig
03
Conditions
Sjögren's syndromeAutoimmune Myopathiespemphigus
Beyond the preview
Go deeper on jRCT2011260057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011260057.